MedTrace Logo

The Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation

NCT07247734 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-12-23

No results posted yet for this study

Summary

The aim for this clinical trial is to evaluate if colchicine in addition to standard of care improves insulin sensitivity in individuals with type 1 diabetes, systemic low-grade inflammaiton and reduced insulin sensitivity. The insulin sensitivity will be evaluated by a hyperinsulinemic, euglycemic clamp.

Conditions

Interventions

DRUG

Colchicin 0.5 mg once daily for two weeks, then twice daily for two weeks

Colchicine treatment in the first period

DRUG

Placebo once daily for two weeks, then twice daily for two weeks

Placebo treatment in the first period

DRUG

Colchicine tablet 0.5 mg once-daily for two weeks, then twice daily for two weeks

Colchicine treatment in the second period

DRUG

Placebo once daily for two weeks, then twice daily for two weeks

Placebo treatment in the second period

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Asger Lund, MD

    lead OTHER

Principal Investigators

  • Asger B Lund, MD, PhD · Center for Clinical Metabolic Research, Gentofte Hospital, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2026-12-22
Completion
2027-06-22

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07247734 on ClinicalTrials.gov